Business, energy, technology, markets and global industry news from Business News Today

France

PharmaDeviceNews France
Stereotaxis completes its Robocath acquisition to expand vascular robotics across interventional cardiology, neurointerventions and electrophysiology. Representative image.
Medical Devices & Diagnostics

Stereotaxis completes Robocath acquisition to expand endovascular robotics platform

Stereotaxis, Inc. has completed its acquisition of French vascular robotics developer Robocath, bringing together two different approaches to controlling medical devices during minimally invasive endovascular procedures. Robocath will be integrated into the United States-based surgical robotics company, which plans to combine its magnetic navigation technology with Robocath’s mechanically controlled platforms for interventional cardiology, neurointerventions and

Read More
VB Spine begins European shipments from new Cestas spine device distribution centre
Medical Devices & Diagnostics

VB Spine opens European distribution hub in France to accelerate spine device deliveries

VB Spine has begun shipping spine surgery products from its newly operational European distribution centre in Cestas, France, giving the privately held medical technology company a more direct logistics base for serving hospitals and clinical customers across the region. The facility, which started accepting orders on June 1, 2026, became fully operational in July and

Read More
Representative image: Dassault Systèmes’ PariSanté Campus partnership highlights Europe’s push to build sovereign healthcare AI, secure health data infrastructure and virtual twin innovation for the next phase of digital health adoption.
Medical Devices & Diagnostics

What Dassault Systèmes’ PariSanté Campus partnership reveals about the future of health data sovereignty

See how Dassault Systèmes and PariSanté Campus could reshape sovereign healthcare AI in Europe. Read the industry analysis.

Read More
Representative image depicting ophthalmic gene therapy research and regulatory review environments. Early access programs are increasingly shaping the approval arc for rare disease gene therapies such as GS010/LUMEVOQ across global markets.
Features & Analysis

Can early access programs reshape the approval arc for rare disease gene therapies?

GenSight Biologics S.A.’s early access rollout of GS010/LUMEVOQ in France and Israel has drawn new attention to how regulators are quietly repurposing compassionate use frameworks into strategic regulatory sandboxes for advanced therapies. As rare disease gene therapies edge closer to commercial viability, a patchwork of early access programs across key jurisdictions is beginning to influence

Read More